Business
NantKwest Executive Chairman Dr. Patrick Soon-Shiong to Present at 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021
EL SEGUNDO, Calif.--(BUSINESS WIRE)-- NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that
About this update from Immunitybio, Inc.
[{"type":"text","content":" EL SEGUNDO, Calif.--(BUSINESS WIRE)--\nNantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that Dr. Patrick Soon-Shiong M.D., Executive Chairman of the Board of Directors, will participate in the 39th Annual J.P. Morgan Healthcare Conference. He will make a formal presentation and answer questions at 5:20 a.m. Pacific Time (8:20 a.m. Eastern Time) on Wednesday, January 13, 2021. Dr. Soon-Shiong will discuss NantKwest’s previously announced agreement to combine in a stock-for-stock transaction with ImmunityBio, Inc. The combination, which is expected to close in the first half of 2021, will create a leading immunotherapy and cell therapy company focused on oncology and infectious disease. Dr. Soon-Shiong will also provide an update on the clinical progress of the two companies’ individual and collaborative therapies.\n\nA live webcast of the presentation and associated presentation materials will be available on the NantKwest website at https://ir.nantkwest.com/ and on the ImmunityBio website at https://immunitybio.com. A replay will be available after the completion of the presentation.\n\nAbout NantKwest\n\nNantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer of clinical dose forms of off-the-shelf natural killer (NK) cell therapies. The activated NK cell platform is designed to destroy cancer and virally-infected cells. The safety of these optimized, activated NK cells—as well as their activity against a broad range of cancers—has been tested in phase I clinical trials in Canada and Europe, as well as in multiple phase I and II clinical trials in the United States. By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs, NantKwest’s goal is to transform medicine by bringing novel NK cell-based therapies to routine clinical care. NantKwest is a member of the NantWorks ecosystem of companies. For more information, please visit www.nantkwest.com.\n\nAbout ImmunityBio\n\nImmunityBio, Inc. is a late stage immunotherapy company developing next-generation therapies that drive immunogenic me...